GSK to Get $1.25 Billion to Settle HIV Drug Patent Row With Gilead

GSK to Get $1.25 Billion to Settle HIV Drug Patent Row With Gilead
A general view of the exterior of the GlaxoSmithKline offices in the Brentford area of London, on Oct. 07, 2021. Leon Neal/Getty Images
Reuters
Updated:

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.

The settlement, announced by GSK on Tuesday, relates to Gilead’s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare’s dolutegravir and other similar compounds.